International Journal of Pharma Insight Studies

3D-Printed Dosage Forms for Personalized Medicine

Dr. Pooja Rani
Division of Clinical Pharmacy, Institute of Advanced Pharma Studies, Chandigarh, India

* Corresponding Author: **Dr. Pooja Rani**

Article Info

Volume: 02
Issue: 02
March-April 2025
Received: 10-02-2025
Accepted: 15-03-2025
Page No: 07-09

Abstract
The advent of three-dimensional (3D) printing technology has revolutionized pharmaceutical manufacturing, enabling the production of personalized dosage forms tailored to individual patient needs. This review explores the application of 3D printing in fabricating customized drug delivery systems, focusing on its potential to enhance therapeutic efficacy, improve patient compliance, and reduce adverse effects. Various 3D printing techniques, such as fused deposition modeling (FDM), stereolithography (SLA), and selective laser sintering (SLS), are discussed alongside suitable pharmaceutical materials. The review also highlights recent advancements, regulatory challenges, and future prospects of 3D-printed medications. By integrating patient-specific factors such as age, weight, and genetic profile, 3D printing paves the way for precision medicine, offering a paradigm shift from traditional "one-size-fits-all" drug formulations.

Keywords: 3D printing, personalized medicine, dosage forms, drug delivery, fused deposition modeling, stereolithography, selective laser sintering, precision medicine

1. Introduction

The pharmaceutical industry has long relied on mass production of standardized dosage forms, often neglecting individual patient variability in drug metabolism, pharmacokinetics, and therapeutic response. Personalized medicine aims to address this limitation by tailoring treatments based on genetic, phenotypic, and lifestyle factors (1). Three-dimensional (3D) printing, an additive manufacturing technique, has emerged as a transformative tool in drug development, allowing for the fabrication of complex, patient-specific dosage forms with precise drug loading and release profiles (2).

Traditional manufacturing methods, such as tablet compression and encapsulation, lack flexibility in dose customization, making them unsuitable for pediatric, geriatric, and patients with rare metabolic disorders (3). In contrast, 3D printing enables the production of small batches of drugs with adjustable dosages, geometries, and release kinetics (4). The U.S. Food and Drug Administration (FDA) approved the first 3D-printed drug, Spritam → (levetiracetam), in 2015, marking a milestone in personalized pharmacotherapy (5).

This review examines the materials, methods, and applications of 3D-printed dosage forms, evaluates current research outcomes, discusses regulatory and technological challenges, and explores future directions in personalized medicine.

2. Materials and Methods

2.1. 3D Printing Technologies in Pharmaceuticals

Several 3D printing techniques have been adapted for pharmaceutical applications:

1. **Fused Deposition Modeling (FDM)**
   - Utilizes thermoplastic polymers (e.g., hydroxypropyl methylcellulose, Eudragit) loaded with active pharmaceutical ingredients (APIs) (6).
   - Allows layer-by-layer extrusion, enabling controlled-release formulations (7).

2. **Stereolithography (SLA)**
   - Uses photopolymerizable resins to create high-resolution structures (8).
   - Suitable for implants and complex drug delivery systems (9).

2.2. Materials for 3D-Printed Dosage Forms

- **Polymers:** Hydrogels, polylactic acid (PLA), polyvinyl alcohol (PVA) (12).
- **Excipients:** Microcrystalline cellulose, mannitol, lactose (13).
- **APIs:** Small molecules, biologics, and combination drugs (14).

2.3. Methodological Workflow

- **Design:** Digital models created using computer-aided design (CAD) software (15).
- **Formulation Optimization:** Selection of polymers and APIs for desired release kinetics (16).
- **Printing:** Layer-by-layer fabrication under controlled conditions (17).
- **Post-Processing:** Drying, polishing, or coating (18).

3. Results

3.1. Customized Drug Release Profiles

- **Immediate-Release Tablets:** FDM-printed formulations with high porosity for rapid dissolution (19).
- **Sustained-Release Systems:** Multi-layered tablets with gradient API distribution (20).

3.2. Patient-Specific Dosage Forms

- **Pediatric Dosing:** Chewable tablets with tailored flavors and dosages (21).
- **Polypills:** Single tablets combining multiple drugs for chronic conditions (22).

3.3. Bioavailability Enhancement

- **Amorphous Solid Dispersions:** Improved solubility of poorly water-soluble drugs (23).
- **Microstructured Tablets:** Enhanced dissolution rates (24).

4. Discussion

4.1. Advantages of 3D-Printed Medications

- **Personalization:** Adjustable dosages based on patient needs (25).
- **Complex Geometries:** Multi-compartment tablets for sequential drug release (26).
- **Reduced Waste:** On-demand manufacturing minimizes overproduction (27).

4.2. Challenges and Limitations

- **Regulatory Hurdles:** Lack of standardized guidelines for 3D-printed drugs (28).
- **Material Limitations:** Few FDA-approved polymers for pharmaceutical use (29).
- **Scalability:** High costs for small-batch production (30).

4.3. Future Perspectives

- **Integration with AI:** Machine learning for optimized drug formulations (31).
- **Bioprinting:** 3D-printed tissues for drug testing (32).

5. Conclusion

3D printing holds immense potential in advancing personalized medicine by enabling the fabrication of patient-specific dosage forms. Despite regulatory and material challenges, ongoing research and technological advancements are expected to overcome these barriers. The future of 3D-printed pharmaceuticals lies in scalable, cost-effective production methods and integration with digital health technologies, ultimately improving therapeutic outcomes and patient adherence.

References

1. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363(4):301-4.
2. Norman J, Madurawe RD, Moore CM, Khan MA, Khairuzzaman A. A new chapter in pharmaceutical manufacturing: 3D-printed drug products. Adv Drug Deliv Rev. 2017;108:39-50.
3. Prasad LK, Smyth H. 3D Printing technologies for drug delivery: a review. Drug Dev Ind Pharm. 2016;42(7):1019-31.
4. Trenfield SJ, Awad A, Goyanes A, Gaisford S, Basit AW. 3D printing pharmaceuticals: drug development to frontline care. Trends Pharmacol Sci. 2018;39(5):440-51.
5. FDA. FDA approves first 3D printed drug product. 2015. [Available from: https://www.fda.gov].
6. Goyanes A, Buanz AB, Basit AW, Gaisford S. Fused-filament 3D printing of drug products: microstructure analysis and drug release characteristics of PVA-based caplets. Int J Pharm. 2015;514(1):290-5.
7. Okwuosa TC, Stefaniak D, Arafat B, Isreb A, Wan KW, Alhnan MA. A lower temperature FDM 3D printing for the manufacture of patient-specific immediate release tablets. Pharm Res. 2016;33(11):2704-12.
8. Wang J, Goyanes A, Gaisford S, Basit AW. Stereolithographic (SLA) 3D printing of oral modified-release dosage forms. Int J Pharm. 2016;503(1-2):207-12.
9. Martinez PR, Goyanes A, Basit AW, Gaisford S. Influence of geometry on the drug release profiles of stereolithographic (SLA) 3D-printed tablets. AAPS PharmSciTech. 2018;19(8):3355-61.
10. Fina F, Goyanes A, Gaisford S, Basit AW. Selective laser sintering (SLS) 3D printing of medicines. Int J Pharm. 2017;529(1-2):285-93.
11. Allahham N, Fina F, Marcuta C, et al. Selective laser sintering 3D printing of orally disintegrating printlets containing ondansetron. Pharmaceutics. 2020;12(2):110.
12. Zhang J, Feng X, Patil H, Tiwari RV, Repka MA. Coupling 3D printing with hot-melt extrusion to produce controlled-release tablets. Int J Pharm. 2017;519(1-2):186-97.
13. Khaled SA, Burley JC, Alexander MR, Roberts CJ. Desktop 3D printing of controlled release pharmaceutical bilayer tablets. Int J Pharm. 2014;461(1-2):105-11.
14. Goyanes A, Wang J, Buanz A, Martínez-Pacheco R, Telford R, Gaisford S, et al. 3D printing of medicines: engineering novel oral devices with unique design and drug release characteristics. Mol Pharm. 2015;12(11):4077-84.
15. Alhnan MA, Okwuosa TC, Sadia M, et al. Emergence of 3D printed dosage forms: opportunities and challenges. Pharm Res. 2016;33(8):1817-32.
16. Scoutaris N, Ross SA, Douroumis D. 3D printed "starmix" drug loaded dosage forms for paediatric

applications. Pharm Res. 2018;35(2):34.
17. Goyanes A, Det-Amornrat U, Wang J, Basit AW, Gaisford S. 3D scanning and 3D printing as innovative technologies for fabricating personalized topical drug delivery systems. J Control Release. 2016;234:41-8.
18. Maroni A, Melocchi A, Parietti F, et al. 3D printed multi-compartment capsular devices for two-pulse oral drug delivery. J Control Release. 2017;268:10-8.
19. Okwuosa TC, Pereira BC, Arafat B, et al. Fabricating a shell-core delayed release tablet using dual FDM 3D printing for patient-centred therapy. Pharm Res. 2017;34(2):427-37.
20. Gioumouxouzis CI, Katsamenis OL, Bouropoulos N, Fatouros DG. 3D printed oral solid dosage forms containing hydrochlorothiazide for controlled drug delivery. J Drug Deliv Sci Technol. 2017;40:164-71.
21. Khaled SA, Burley JC, Alexander MR, Yang J, Roberts CJ. 3D printing of tablets containing multiple drugs with defined release profiles. Int J Pharm. 2015;494(2):643-50.
22. Goyanes A, Kobayashi M, Martínez-Pacheco R, et al. Fused-filament 3D printing of drug products: microstructure analysis and drug release characteristics of PVA-based caplets. Int J Pharm. 2016;514(1):290-5.
23. Zhang J, Yang W, Vo AQ, et al. Hydroxypropyl methylcellulose-based controlled release dosage by melt extrusion and 3D printing: structure and drug release correlation. Carbohydr Polym. 2017;177:49-57.
24. Sadia M, Arafat B, Ahmed W, et al. Channelled tablets: an innovative approach to accelerating drug release from 3D printed tablets. J Control Release. 2018;269:355-63.
25. Norman J, Madurawe RD, Moore CM, Khan MA, Khairuzzaman A. A new chapter in pharmaceutical manufacturing: 3D-printed drug products. Adv Drug Deliv Rev. 2017;108:39-50.
26. Goyanes A, Allahham N, Trenfield SJ, et al. Direct powder extrusion 3D printing: fabrication of drug products using a novel single-step process. Int J Pharm. 2019;567:118471.
27. Awad A, Trenfield SJ, Gaisford S, Basit AW. 3D printed medicines: A new branch of digital healthcare. Int J Pharm. 2018;548(1):586-96.
28. US FDA. Technical considerations for additive manufactured medical devices. 2017.
29. Preis M, Öblom H. 3D-printed drugs for children—are we ready yet? AAPS PharmSciTech. 2017;18(2):303-8.
30. Trenfield SJ, Awad A, Goyanes A, Gaisford S, Basit AW. 3D printing pharmaceuticals: drug development to frontline care. Trends Pharmacol Sci. 2018;39(5):440-51.
31. Varghese R, Salvi S, Sood P, Karsiya J, Kumar D. 3D printed medicines: A prospective branch in personalized medicine. J Drug Deliv Sci Technol. 2022;68:103106.
32. Knowlton S, Onal S, Yu CH, et al. Bioprinting for cancer research. Trends Biotechnol. 2015;33(9):504-13.